2023 Pharma Outlook – trends shaping the year ahead

6 January 2023

Professional services company PwC has released a new report, PwC’s Next In Pharma and Life Sciences 2023 Report. This highlights the outlook for the pharmaceutical and life sciences industry, and the biggest c-suite agenda topics that will shape 2023.

Amid high inflation, talent shortages, rising capital costs, blockbuster patent expiries and the impact of the IRA – 90% of executives are worried about the macroeconomic environment. But according to the report, companies can seize this moment to transform their business in bold new ways.

In 2023, companies will need to reimagine work, tech-enable their organizations, and advance their portfolios to achieve multiple objectives simultaneously.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK